Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
DAPA01
Approved small_molecule active
Quick answer
Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy for Fontan is a Approved program (small_molecule) at The University of Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The University of Hong Kong
- Indication
- Fontan
- Phase
- Approved
- Modality
- small_molecule
- Status
- active